Biogen Options Trading: A Deep Dive into Market Sentiment

Recent analysis shows a clear bullish sentiment among large investors regarding Biogen (NASDAQ: BIIB). This trend should not be overlooked, as our recent findings indicate a significant upswing in options trading activity. The identities of these investors are currently unknown, but their actions often signal important market movements.

Today, our tracking revealed that Benzinga's options scanner has detected a remarkable 11 instances of unusual options trading related to Biogen. Such a level of activity suggests a strong interest in the stock, which typically points to anticipated changes in the company’s market dynamics.

Market Sentiment Overview

The outlook among these influential investors appears to be split. Currently, 36% of the activity is bullish, while 27% is bearish. Among the significant trades recorded, there are 3 put options totaling $154,362 and 8 call options amounting to $325,022. This imbalance highlights a more optimistic view towards Biogen's future performance.

Price Predictions and Targets

From the trading behaviors observed, it appears that these investors are targeting a price range for Biogen between $120.00 and $155.00 over the recent three months. Keeping an eye on the stock’s movement within this range will be crucial for traders and investors alike.

Volume and Open Interest Trends

When engaging in options trading, analyzing volume and open interest is vital for gauging liquidity and investor interest. Recent data shows the evolution of volume and open interest for calls and puts associated with Biogen over the past 30 days, specifically within the targeted strike price range of $120.00 to $155.00.

Key Options Trades from the Last Month

Symbol	PUT/CALL	Trade Type	Sentiment	Exp. Date	Ask	Bid	Price	Strike Price	Total Trade Price	Open Interest	Volume
BIIB	PUT	SWEEP	BEARISH	07/18/25	$9.7	$9.5	$9.7	$135.00	$72.7K	479	1
BIIB	CALL	SWEEP	NEUTRAL	03/21/25	$5.3	$5.1	$5.2	$140.00	$52.0K	122	113
BIIB	CALL	TRADE	BULLISH	03/21/25	$20.5	$19.9	$20.5	$120.00	$51.2K	1.0K	115
BIIB	CALL	SWEEP	BULLISH	07/18/25	$9.7	$9.6	$9.7	$150.00	$49.4K	119	3
BIIB	CALL	TRADE	NEUTRAL	03/21/25	$12.6	$11.9	$12.3	$130.00	$49.2K	149	0

About Biogen

Formed by the merger of Biogen and Idec in 2003, Biogen has since made significant strides in the biopharmaceutical space, particularly in multiple sclerosis and oncology drugs. Its notable products include Avonex (multiple sclerosis), Rituxan (cancer), and newer medications such as Spinraza for spinal muscular atrophy and Leqembi for Alzheimer's Disease. The company continues to advance its pipeline with several candidates in phase 3 trials.

Current Market Position of Biogen

• At present, Biogen's trading volume stands at 601,076, and its price has seen an increase of 2.28%, currently listed at $140.21.
• Relative Strength Index (RSI) readings suggest the stock is balanced between overbought and oversold territory.
• The company is set to announce its earnings in 61 days.

Analyst Ratings for Biogen

Five market analysts have recently reviewed Biogen, leading to a consensus target price of $170.60. Individual ratings include:

Scotiabank: Sector Outperform rating; price target of $224.
Citigroup: Neutral rating; price target of $145.
Truist Securities: Buy rating; price target of $210.
BMO Capital: Market Perform rating; price target of $139.
Piper Sandler: Neutral rating; price target adjusted to $135.

Understanding Options Trading Risks

Engaging in options trading can be risky but offers potential rewards. Savvy traders manage these risks by continually educating themselves and adjusting strategies based on changing market conditions. For those interested, real-time alerts on Biogen's options trades are available to help track market movements.

Biogen, Options, Trading